BURLINGTON, Mass., Jan. 21 /PRNewswire-FirstCall/ -- Palomar Medical
Technologies Inc (Nasdaq: PMTI) is a leading researcher and developer of
proprietary laser and other light-based systems for hair removal and other
cosmetic treatments. The Company will be presenting its latest products at the
American Academy of Dermatology's 62nd Annual Meeting (AAD), in Washington,
DC, from February 7 to 10, 2004, and will be available to give investor
demonstrations and discuss it's full line of products at the Washington DC
Convention Center, booth #3137.
At the meeting, Palomar will introduce it's next generation of Lux pulsed-
light system. The Palomar portfolio currently includes the MediLux(TM),
EsteLux(TM) and NeoLux(TM), which are sold with the LuxY(TM) handpiece for
hair removal and pigmented lesion treatment on large body areas; the LuxG(TM)
handpiece for photofacial treatments on vascular and pigmented lesions; the
LuxR(TM) handpiece for large-area hair removal on all skin types; the
LuxRs(TM) handpiece for permanent hair reduction on all skin types with fewer
treatments; the LuxV(TM) handpiece for fast treatment of pigmented lesions and
mild to moderate acne (pending FDA clearance); and the LuxB(TM) handpiece for
treatment of lighter pigmented lesions on fair skin as well as leg and spider
veins. With the various Lux handpieces, physicians can tailor a system to
their existing practice or offer additional applications to their patients at
a fraction of competing systems. The Market acceptance of the Lux family of
products has helped the Company increase its revenues, profit and cash
position over the last two years. The Company also sells the Palomar Q-YAG
5(TM) laser system for tattoo and pigmented lesion removal.
Palomar's light-based cosmetic technology is among the most advanced in
the industry. Palomar invested considerable resources to ensure that its
patent portfolio and other intellectual property provide strong protection of
its technology.
To reserve a time to meet with Palomar management and/or receive product
demonstrations, please contact Palomar's Investor Relations' department at
781-993-2411 or ir@palomarmedical.com.
About Palomar Medical Technologies Inc: Palomar is a leading researcher
and developer of light-based systems for hair removal and other cosmetic
treatments. Last year, Palomar and The Gillette Company (NYSE: G) entered into
an agreement to complete development and commercialize a patented home-use,
light-based hair removal device for women. New and exciting indications are
being tested to further advance the hair removal market and other cosmetic
applications. Palomar pioneered the optical hair removal field, when, in 1997,
it introduced the first high-powered laser hair removal system. Since then,
many of the major advances in light-based hair removal have been based on
Palomar technology. There are now millions of light-based cosmetic procedures
performed around the world every year in physician offices, clinics, spas and
salons.
For more information on Palomar and its products, visit Palomar's website
at http://www.palomarmedical.com. To continue receiving the most up-to-date
information and latest news on Palomar as it happens, sign up to receive
automatic e-mail alerts by going to the E-mail Alerts page in the Investor
Relations' section of the website.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, challenges in managing joint ventures and
research with third parties, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether
FDA clearance will be obtained for future products, the results of litigation,
difficulties in collecting royalties, potential infringement of third-party
intellectual property rights, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on Form 10-K
for the year ended December 31, 2002 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these forward-
looking statements, which speak only as of the date hereof. The Company
undertakes no obligation to release publicly the result of any revisions to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
Contacts:
Paul S. Weiner
Chief Financial Officer
Palomar Medical Technologies Inc
781-993-2411
ir@palomarmedical.com
SOURCE Palomar Medical Technologies, Inc
 back to top
Related links:
http://www.palomarmedical.com
Company News On-Call:
http://www.prnewswire.com/comp/107555.html
CONTACT:
Paul S. Weiner, Chief Financial Officer of
Palomar Medical Technologies Inc, +1-781-993-2411,
ir@palomarmedical.com
|
